Email Alerts
RSS
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  CHINESE JOURNAL OF BURNS AND WOUNDS  > 2022  >  38(6): 506-511
Zhao JF,Hao DF,Li T,et al.Analysis of clinical features and treatment of pyoderma gangrenosum[J].Chin J Burns Wounds,2022,38(6):506-511.DOI: 10.3760/cma.j.cn501225-20220317-00068.
Citation: Zhao JF,Hao DF,Li T,et al.Analysis of clinical features and treatment of pyoderma gangrenosum[J].Chin J Burns Wounds,2022,38(6):506-511.DOI: 10.3760/cma.j.cn501225-20220317-00068.
shu

Analysis of clinical features and treatment of pyoderma gangrenosum

doi: 10.3760/cma.j.cn501225-20220317-00068

  • Wound Repair and Reconstruction Center, Beijing Fucheng Hospital, Beijing 100143, China

More Information
    Abstract
  •   Objective  To explore the clinical features and treatment of pyoderma gangrenosum (PG).  Methods  A retrospective observational study was conducted. From January 2012 to July 2021, 25 patients with PG who met the inclusion criteria were admitted to Beijing Fucheng Hospital, including 16 males and 9 females, with the age of onset of disease being 14 to 75 years. Among them, the classification of PG identified 17 cases of ulcerative type, 6 cases of pustular type, 1 case of proliferative type, and 1 case of bullous type. Six patients were accompanied with systemic diseases, while 19 patients were not accompanied with systemic diseases. At the same time of systemic treatment with glucocorticoids, dressing changes or surgical skin grafting was performed on the wounds. The results of laboratory and histopathological examinations, the overall curative effects and follow-up of patients, the wound healing time of patients with negative and positive microbial culture results of wound secretion specimens, and the curative effects of patients with and without systemic diseases were analyzed.  Results  The results of blood routine examination of 19 patients were abnormal, and all the immunological indexes were normal in all the patients; the microbial culture results of wound secretion specimens were positive in 14 patients; and the histopathological examination results of ulcer boundary tissue in 15 patients with rapid wound progress were mainly local tissue inflammatory changes. The wounds were cured in 17 patients, mostly healed in 7 patients, and not healed in 1 patient. After one-year's follow-up, the PG in 3 patients relapsed due to self-discontinuation of medication after discharge, and the wounds were healed gradually after adjustment of medication, while the remaining patients had no relapse. The days of wound healing in 14 patients with positive microbial culture results of wound secretion specimens were 21-55 days, and the days of wound healing in 11 patients with negative microbial culture results in wound secretion specimens were 20-54 days. In the 6 patients with systemic diseases, the wounds of 3 patients were cured, and the wounds of the other 3 patients were mostly healed. In the 19 patients without systemic diseases, the wounds of 14 patients were cured, the wounds of 4 patients were mostly healed, and the wound of 1 patient was not healed.  Conclusions  The laboratory examination and pathological manifestations of patients with PG lacks characteristics, and their clinical manifestations are rich and diverse, thus PG can be easily misdiagnosed. The glucocorticoids combined with immunosuppressive therapy have good effects on PG. Surgical intervention can be performed on the wounds. Specifically, excessive debridement is not recommended in the acute phase, but skin grafting can be performed in the contraction phase.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    GoldustM,HagstromEL,RathodD, et al.Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J].Expert Rev Clin Pharmacol,2020,13(2):157-161.DOI: 10.1080/17512433.2020.1709825.
    [2]
    Santa LuciaG, DeMaioA, KarlinS, et al. A case of extracutaneous pyoderma gangrenosum in a patient with persistent cutaneous and systemic symptoms: implications for differential diagnosis and treatment[J].JAAD Case Rep,2021,15:85-87.DOI: 10.1016/j.jdcr.2021.07.019.
    [3]
    JinSY, ChenM, WangFY, et al. Applying intravenous immunoglobulin and negative-pressure wound therapy to treat refractory pyoderma gangrenosum: a case report[J].Int J Low Extrem Wounds,2021,20(2):158-161.DOI: 10.1177/1534734620940459.
    [4]
    GeorgeC,DeroideF,RustinM.Pyoderma gangrenosum - a guide to diagnosis and management[J].Clin Med (Lond),2019,19(3):224-228.DOI: 10.7861/clinmedicine.19-3-224.
    [5]
    SasorSE,SoleimaniT,ChuMW,et al.Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases[J].J Wound Care,2018,27(Suppl 1):S4-8.DOI: 10.12968/jowc.2018.27.Sup1.S4.
    [6]
    PlatzerKD,KostnerL,VujicI,et al.Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation[J].J Eur Acad Dermatol Venereol,2019,33(12):e474-e475.DOI: 10.1111/jdv.15803.
    [7]
    IlterN,KeskinN,AdisenE,et al.Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma mimicking pyoderma gangrenosum[J].Australas J Dermatol,2021,62(4):e605-e607.DOI: 10.1111/ajd.13708.
    [8]
    PinardJ, ChiangDY, MostaghimiA, et al. Wounds that would not heal: pyoderma gangrenosum[J].Am J Med,2018,131(4):377-379.DOI: 10.1016/j.amjmed.2017.12.009.
    [9]
    BordaLJ, WongLL, MarzanoAV, et al.Extracutaneous involvement of pyoderma gangrenosum[J].Arch Dermatol Res,2019,311(6):425-434.DOI: 10.1007/s00403-019-01912-1.
    [10]
    ZhangXH, JiaoY. Takayasu arteritis with pyoderma gangrenosum: case reports and literature review[J].BMC Rheumatol,2019,3:45.DOI: 10.1186/s41927-019-0098-z.
    [11]
    ChakiriR,BaybayH,HatimiAE,et al.Clinical and histological patterns and treatment of pyoderma gangrenosum[J].Pan Afr Med J,2020,36:59.DOI: 10.11604/pamj.2020.36.59.12329.
    [12]
    冯尘尘,杨转花,李高洁,等. 坏疽性脓皮病诊疗研究进展[J]. 中国麻风皮肤病杂志,2022,38(6):414-418. DOI: 10.12144/zgmfskin202206414.
    [13]
    AbdelmaksoudA.Pyoderma gangrenosum: a clinical conundrum[J]. J Eur Acad Dermatol Venereol,2018,32(10):e381-e382.DOI: 10.1111/jdv.14977.
    [14]
    KimYJ,YangHJ,LeeMW,et al.Cutaneous indicator of myelodysplastic syndrome: sudden bullous pyoderma gangrenosum[J].Jpn J Clin Oncol,2020,50(8):958-959.DOI: 10.1093/jjco/hyz207.
    [15]
    傅汝倩, 康志娟, 李志辉. 化脓性关节炎、坏疽性脓皮病和痤疮综合征孪生兄弟报道[J]. 中华实用儿科临床杂志, 2021, 36(5): 382-384. DOI: 10.3760/cma.j.cn101070-20191015-00985.
    [16]
    Martinez-RiosC, JariwalaMP, HighmoreK, et al. Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature[J].Pediatr Radiol,2019,49(1):23-36.DOI: 10.1007/s00247-018-4246-1.
    [17]
    FeldmanSR, LacyFA, HuangWW. The safety of treatments used in pyoderma gangrenosum[J]. Expert Opin Drug Saf,2018,17(1):55-61.DOI: 10.1080/14740338.2018.1396316.
    [18]
    HrinML,BashyamAM,HuangWW,et al.Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review[J].Int J Dermatol,2021,60(12):e486-e492.DOI: 10.1111/ijd.15539.
    [19]
    McKenzieF, CashD, GuptaA, et al.Biologic and small molecule medications in the management of pyoderma gangrenosum[J].J Dermatolog Treat,2019,30(3):264-276.DOI: 10.1080/09546634.2018.1506083.
    [20]
    信跃文,柴艳芬,姚咏明.皮肤调节性T细胞与创面愈合及免疫疾病的关系研究进展[J].中华烧伤杂志,2020,36(2):156-160.DOI: 10.3760/cma.j.issn.1009-2587.2020.02.015.
    [21]
    HoffmanKP, ShearerS, ChungC, et al.Clinical and therapeutic overlap of pyoderma gangrenosum, cutaneous small vessel vasculitis, and immunoglobulin A[J].Int J Dermatol,2020,59(8):e286-e288. DOI: 10.1111/ijd.14841.
    [22]
    王克甲,王耘川,计鹏,等.手术治疗坏疽性脓皮病一例[J].中华烧伤杂志,2016,32(3):187-188.DOI: 10.3760/cma.j.issn.1009-2587.2016.03.014.
    [23]
    OuazzaniA, BertheJV, de FontaineS.Post-surgical pyoderma gangrenosum: a clinical entity[J]. Acta Chir Belg, 2007,107(4):424-428. DOI: 10.1080/00015458.2007.11680088.
    [24]
    陈宾,李叶扬,梁岷,等.坏疽性脓皮病误诊为皮肤感染性溃疡一例[J].中华烧伤杂志,2015,31(3):230-231.DOI: 10.3760/cma.j.issn.1009-2587.2015.03.020.
    [25]
    WangJY, FrenchLE, ShearNH, et al.Drug-induced pyoderma gangrenosum: a review[J]. Am J Clin Dermatol,2018,19(1):67-77. DOI: 10.1007/s40257-017-0308-7.
    [26]
    曾琳茜,姚越,黄欣,等.生物制剂在坏疽性脓皮病治疗中的研究进展[J/OL].中国皮肤性病学杂志,2022(2022-03-17)[2022-04-22]. https://kns.cnki.net/kcms/detail/detail.aspx?doi=10.13735/j.cjdv.1001-7089.202110142. [网络预发表]. https://kns.cnki.net/kcms/detail/detail.aspx?doi=10.13735/j.cjdv.1001-7089.202110142
    [27]
    SongH,LahoodN,MostaghimiA.Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series[J].Br J Dermatol, 2018, 178(2):363-368.DOI: 10.1111/bjd.15850.
    [28]
    吴超,晋红中.坏疽性脓皮病的辅助检查及治疗[J].中华临床免疫和变态反应杂志,2019,13(4):301-305.DOI: 10.3969/j.issn.1673-8705.2019.04.010.
    [29]
    刘崔.坏疽性脓皮病的临床特点及治疗分析[J/CD].临床检验杂志:电子版,2017,6(2):290-291.
    [30]
    Di GuidaA, FabbrociniG, ScalvenziM, et al.Coexistence of bullous pemphigoid and pyoderma gangrenosum[J].J Clin Aesthet Dermatol,2022,15(1):16-17.
    [31]
    HaJW, HahmJE, KimKS, et al. A case of pyoderma gangrenosum with myelodysplastic syndrome[J].Ann Dermatol,2018,30(3):392-393.DOI: 10.5021/ad.2018.30.3.392.
    [32]
    HaagC, HansenT, HajarT, et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum[J].J Invest Dermatol,2021,141(1):59-63.DOI: 10.1016/j.jid.2020.04.019.
    [33]
    吴超,方凯,晋红中.泼尼松联合依那西普治疗并发坏疽性脓皮病的关节病性银屑病[J].临床皮肤科杂志,2016,45(3):197-199.DOI: 10.16761/j.cnki.1000-4963.2016.03.014.
    [34]
    BaltazarD, HaagC, GuptaAS, et al.A comprehensive review of local pharmacologic therapy for pyoderma gangrenosum[J].Wounds,2019,31(6):151-157.
    [35]
    褚万立,郝岱峰,赵景峰,等. 慢性创面外露内置物的保全和创面修复临床策略[J]. 中华烧伤杂志,2020,36(6):484-487. DOI: 10.3760/cma.j.cn501120-20190215-00027.
    [36]
    QureshiA,PersaudK,ZulfiqarS, et al.Atypical pyoderma gangrenosum: a case of delayed recognition[J].J Community Hosp Intern Med Perspect,2021,11(2):242-248. DOI: 10.1080/20009666.2020.1866250.
    [37]
    Penalba-TorresM,Zarco-OlivoC,Calleja-AlgarraA.Postsurgical pyoderma gangrenosum: a diagnosis we cannot miss[J].Med Clin (Barc),2021,157(12):597.DOI: 10.1016/j.medcli.2021.02.019.
    [38]
    高琼,薛晓东.创面床准备的研究进展[J].临床医学研究与实践,2017,2(28):194-196.DOI: 10.19347/j.cnki.2096-1413.201728096.
    [39]
    吴新果,黄茜,周小勇.糖皮质激素联合环孢素A治疗溃疡型坏疽性脓皮病1例[J].中国皮肤性病学杂志,2015,29(11):1203,1207.DOI: 10.13735/j.cjdv.1001-7089.201411011.
    [40]
    吴志华,郭红卫.糖皮质激素作用机制进展及在皮肤科中的应用[J].皮肤病与性病,2011,33(6):321-324,339.DOI: 10.3969/j.issn.1002-1310.2011.06.004.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (995) PDF downloads(44) Cited by()
    Proportional views
    Related

    Copyright © Chinese Journal of Burns京ICP备07035254号-14

    E-mail：shaoshangzazhi@163.com

    Website：https://zhsszz.xml-journal.net/

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return